by TractManager | Jun 15, 2016 | Emerging Technology Report
An investigational checkpoint inhibitor proposed as a third-line treatment for advanced non-small cell lung cancer in patients whose disease expresses programmed death-ligand 1 (PD-L1). If you have a Hayes login, click here to view the full report on the...
by TractManager | Jun 9, 2016 | Emerging Technology Report
A monoclonal antibody to treat multiple myeloma in patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulator, or who are double refractory to these agents.If you have a Hayes login, click here to view the...
by TractManager | Jun 9, 2016 | Molecular Test Assessment
Uveal melanoma (UM) is the most common form of primary eye cancer. The incidence of UM in the United States is approximately 4.3 cases per million. UM is more common in older individuals, with incidence rates peaking at age 70, and is associated with...
by TractManager | Jun 9, 2016 | Health Technology Assessment
Purpose of Technology: Atrial fibrillation (AF) is a supraventricular, accelerated heart rhythm characterized by uncoordinated atrial activation that leads to inefficient, irregular atrial contraction. Minimally invasive catheter ablation procedures, such as...
by TractManager | Jun 2, 2016 | Health Technology Assessment
Purpose of Technology: Patients with chronic myelogenous leukemia (CML) have an overproduction of partially mature white blood cells of the myeloid lineage. High doses of chemotherapy and/or radiotherapy can destroy bone marrow producing the abnormal cells but normal...
Recent Comments